Haemonetics price target raised to $93 from $90 at Barrington

5 days ago 3

Barrington raised the firm’s price target connected Haemonetics (HAE) to $93 from $90 and keeps an Outperform standing connected the shares aft the institution announced that it had acquired Vivasure Medical Limited, an Ireland-based developer of precocious polymer implants and transportation systems. The steadfast is expanding its price target based connected a affirmative presumption of the Vivasure transaction, the expert tells investors.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected HAE:

Disclaimer & DisclosureReport an Issue

Haemonetics acquires Vivasure to grow structural bosom portfolio
Haemonetics acquires Vivasure Medical for EUR 100M
Haemonetics terms people raised to $90 from $75 astatine Mizuho
Haemonetics terms people raised to $99 from $87 astatine Baird
Haemonetics downgraded to Hold from Buy astatine Needham

Read Entire Article